0

Highly Stable Plasminogen Activator Inhibitor Type One (VLHL PAI-1) Protects Fibrin Clots From Tissue Plasminogen Activator-Mediated Fibrinolysis

Jerzy Jankun, Ansari M Aleem, Steven H Selman, Ewa Skrzypczak-Jankun, Wieslawa Lysiak-Szydlowska, Nicholas Grafos, Hugh J L Fryer, Robert S Greenfield

Int J Mol Med. 2007 Nov;20(5):683-7.

PMID: 17912461

Abstract:

Plasminogen activator inhibitor-1 (PAI-1) is the major specific inhibitor of tissue-type plasminogen activator (tPA) which mediates fibrin clot lysis through activation of plasminogen. Wild-type-PAI-1 (wPAI-1) is rapidly converted to the latent form (half-life of approximately 2 h) and loses its ability to inhibit tPA. We developed a very long half-life PAI-1 (VLHL PAI-1), a recombinant protein with a half-life >700 h compared with wPAI-1. In this study, VLHL PAI-1 was assessed for its ability to inhibit clot lysis in vitro. Clot formation was initiated in normal plasma supplemented with tPA by the addition of either tissue factor or human recombinant FVIIa. Clot lysis time, monitored turbidimetrically in a microtiter plate reader, was determined at various concentrations of wPAI-1 and VLHL PAI-1. Both wPAI-1 and VLHL PAI-1 caused a significant increase in clot lysis time, although the latter was somewhat less effective at lower concentrations. The VLHL PAI-1, but not wPAI-1, maintained its anti-fibrinolytic activity after preincubation overnight at 37 degrees. These studies demonstrate that VLHL PAI-1 is an effective inhibitor of fibrin clot degradation. Due to the high stability of VLHL PAI-1 compared with wPAI-1, this novel inhibitor of tPA-mediated fibrinolysis may have therapeutic applications for treating surgical and trauma patients when used directly or in conjunction with the procoagulant recombinant FVIIa.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR42415751 Plasminogen Activator Inhibitor-1, Human, Recombinant Plasminogen Activator Inhibitor-1, Human, Recombinant Price
qrcode